Biosimilars differ from original biologic products and cannot be treated in the same way as generic small molecule medications in terms of development and regulatory approval (Declerck et al. 2017)., Read more...
Want to receive push notifications for all major on-site activities?
You must be logged in to post a comment.
You must be logged in to post a comment.